
price close busi juli
intuit surgic manufactur da vinci robot
system use wide rang minimally-
biomed devic servic
surg-i-rrif bullish trend emerg strong
print buy target
bottom line deliv upsid top- bottom-lin via strong
procedur growth amid expand geograph procedur footprint guidanc
slightli increas vs previous strong underli
trend coalesc bullish thesi stock inde see ramp
util robot surgeri expect chart cours signific
increas time global procedur surgic robot backdrop
think double-digit procedur growth firm could sustain sever year
come estim
wit continu believ robot surgeri revolut still earli inning note
penetr applic procedur today still quit low estim
applic penetr procedur rel procedur
moreov see surgic robot expand via enabl technolog
sp ion advanc imag ai machine-learn geograph expans japan
china south america emea inde firm commit robust invest
new technolog new market account
portend surgic robot could expand pace
dissimilar robot procedur growth rate penetr profil
could look attract year today what
think expand would allow plenti opportun impend competit
without materi impact growth potenti notwithstand belief
maintain domin via robust portfolio regulatori approv larg
instal base y/i commit stay ahead
recommend ad posit common amid expect susten
strong busi trend robust procedur growth estim
expand demand system demand davinci access highlight
earn call strong/increas revenu per procedur
us procedur trend procedur growth revenue/procedur two
import metric stori key driver long-term revenu earn
growth view remain strong posit procedur dynam support
increas procedur guidanc high end prior rang
notabl note moder elit growth exhibit sever
quarter hernia colon resect procedur growth rate bariatr
cholecystectomi acceler impli overal demand gener surgeri remain
robust inde hernia repair launch year ago open
market davinci gener surgeri util expand broader set
gener surgeri procedur excess procedur capac davinci evapor
mani case one reason think see strong us capit growth
expect
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
us procedur trend continu wit think slight moder hernia
procedur quarter may due surgeon enough
access robot gener surgeri procedur daili
docket regularli sum think impli strong market backdrop
abl expand capit footprint next sever
quarter regard last point invest significantli expand
domest commerci sale footprint recent support
asia market updat bullish signal display china place first
system associ region new system quota
eight system place quarter experienc deceler
procedur growth trend region past sever quarter due capac
constraint associ current instal system note revers
procedur growth trend heel system placement see
bullish sign illustr high level demand robot region
go forward given somewhat protract timelin associ
tender process expect impact quota becom
pronounc late provid anoth vector
procedur growth next sever year estim china
current repres isrg total revenu see upsid go
forward system instal could potenti tripl region also note
quota cover approv robot platform given timelin associ
upcom main potenti robot competitor expect
captur larg share quota entrench compani region
ahead impend competit turn japan deliv strong
procedur growth tend past sever quarter heel newli
reimburs procedur growth moder vs recent level
ran comp associ newli reimburs procedur think
system placement region new system highlight bullish
potenti region continu strong demand new
center look expand surgic practic well exist center
look upgrad isrg latest technolog continu view initi
adopt trend on-going system placement japan portend posit
long-term procedur volum growth region especi given reimburs
line laparoscop level suggest desir perform procedur via
robot approach region strong expect japan china
latter begin materi second half
serv tailwind busi near medium term
sp initi limit launch on-going announc fda clearanc
urolog surgic procedur da vinci sp singl port system last june
firm commenc measur launch platform
system total ship us market instal
addit six system bring total instal base manufactur
constraint limit total system placement current quarter firm
instal addit system work past manufactur
constraint bring total clinic instal base us specif
platform carri urolog recent tor indic
vast major procedur perform today least uro indic
like cannibalist isrg current busi expect recent
approv tor indic support volum growth increment robot
procedur market expans addit procedur futur sp indic
submiss name colorect expect prove
import isrg overal busi augment total procedur growth
buy unchang target price juli
biomed devic servic
expand specif surgic robot gener
next decad
guidanc updat manag today refin outlook total
procedur volum growth expect rang high end
firm recent updat guidanc rang firm initi guid
procedur growth rang firm also increas pro
forma gm expect high end previous provid rang
manag maintain total opex project continu
expect total expens increas level firm continu
project incom tax rang
figur intuit surgic result vs cg estim consensu project
buy unchang target price juli
biomed devic servic
deriv price target appli premium mean large-cap
med-tech price-to-earnings multipl appli ep model
forward ep compound-annual-growth-rate thu aforement target multipl drive
target price-to-earnings appli pro forma ep estim
deriv target
buy unchang target price juli
biomed devic servic
p/e/g valuat financi metric use mean ex-outli large-cap med-tech price-to-earnings p/e/g multipl ep pro forma growth b/c price-to-earnings multipl use group forma price figur incom statement
compani report canaccord genuiti estim detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact
inform appear front page report
buy unchang target price juli
biomed devic servic
million except per share total servic total gross total oper oper incom expens pre-tax incom tax expens tax incom net loss attribut nonconttol interest jv- net incom attribut share ep pro-forma calcul xi trade-in programshar base compens intang liabil litig relat invest attribut non-controlling interest net forma ex tax analysisduct adjust sbc ia margin pro margin includ margin pro incom cont figur revenu model
buy unchang target price juli
biomed devic servic
total instrument/access total servic total revenu growth modelgrowth rate assumptionsu system unit sale replacements/trad ins/retir instal base us total total sold ex-oper asp leas total asp per oper modelgrowth rate procedur growth procedur growth procedur growth gener ou urolog gener gynecolog us ww procedur asp revenue/instal system intuit surgic
